

A CONCISE TEXTBOOK ON MELANOMA

Authors

Dr. Vignesh NR

Assistant Professor, Department of DVL, Sree Balaji Medical College & Hospital, Chennai,
Tamil Nadu, India

Dr. Sukanya G

Associate Professor, Department of DVL, Sree Balaji Medical College & Hospital, Chennai,
Tamil Nadu, India

Co-Authors:

Dr. Ramesh TV

Assistant Professor, Department of DVL, Sree Balaji Medical College & Hospital, Chennai,
Tamil Nadu, India

Dr. Sane Roja Renuka

Senior Resident, Department of DVL, Sree Balaji Medical College & Hospital, Chennai,
Tamil Nadu, India

Prof. K. Manoharan

Prof & HOD, Department of DVL, Sree Balaji Medical College & Hospital, Chennai, Tamil
Nadu, India

Editorial Office

Prof.K.Manoharan
Professor and Head of Department,
Department of DVL,
Sree Balaji Medical College & Hospital,
7, CLC Works Road, Chromepet, Chennai 600044,
Tamil Nadu, India

Email ID : dvlsbmch@bharathuniv.ac.in

ISBN Number : 978-93-5457-289-0

Edition: 1 - 2021 (Self Published)

Printer Details:

NETWAY PRINTS

AN Elumalai Salai, Moovendar Nagar
Iyyaappanthangal
Chennai 600077

These drugs are now the first line therapy for metastatic melanoma. They are more effective as monotherapy. They also produce vitiligo like depigmentation when there is good clinical response.

Other treatment modalities include high dose interleukin 2, cancer vaccines and adoptive cell therapy.

PROGNOSTIC FACTORS:

1. Mitotic rate- 0 good prognosis;6 bad prognosis
2. Ulceration- bad prognosis
3. Location-hair bearing regions have good prognosis
4. Women have good prognosis
5. Younger patients have good prognosis
6. Leukoderma- good prognosis
7. Regression-poor prognosis
8. Presence of tumour infiltrating lymphocytes- good prognosis

References:

1. Garbe C, Leiter U Melanoma epidemiology and trends Clin Dermatol 2009;27:3–9
2. Davies H, Bignell GR, Cox C, et al Mutations of the BRAF gene in human cancer Nature 2002;417:949–54
3. Buettner PG, Leiter U, Eigentler TK, Garbe C Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society Cancer 2005;103:616–24
4. Lasithiotakis K, Leiter U, Meier F, et al Age and gender are significant independent predictors of survival in primary cutaneous melanoma Cancer 2008;112:1795–804
5. Potrony M, Badenas C, Aguilera P, et al Update in genetic susceptibility in melanoma Ann Transl Med 2015;3:210
6. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O Association of early malignant melanoma with nevocytic nevi Cancer 1989;63:550–5
7. Gandini S, Sera F, Cattaruzza MS, et al Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure Eur J Cancer 2005;41:45–60

8. Bauer J, Buttner P, Wiecker TS, et al Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children *Int J Cancer* 2005;115:121–6
9. Green AC, Williams GM, Logan V, Strutton GM Reduced melanoma after regular sunscreen use: randomized trial follow-up *J Clin Oncol* 2011;29:257–63
10. Grob JJ, Bonerandi JJ The ‘ugly duckling’ sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening *Arch Dermatol* 1998;134:103–4
11. Garbe C, Buttner P, Bertz J, et al Primary cutaneous melanoma Identification of prognostic groups and estimation of individual prognosis for 5093 patients *Cancer* 1995;75:2484–91
12. Garbe C, Peris K, Hauschild A, et al Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline *Eur J Cancer* 2010;46:270–83